Amwell vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
B2B telehealth infrastructure for health systems with $275M revenue; white-label digital care platform with AI Automated Care Programs for chronic disease management.
About
Amwell (American Well) is a telehealth platform company providing virtual care infrastructure for health systems, payers, employers, and government agencies — enabling digital health visits across primary care, urgent care, behavioral health, specialty care, and automated care programs. Founded in 2006 in Boston by Roy and Ido Schoenberg and listed on NYSE in 2020, Amwell generates approximately $275 million in annual revenue serving over 2,000 health systems, 80+ health plan clients, and 80+ government programs.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.